Phase 1 N=39 ASSIST: Treatment for Childhood Apraxia of Speech
Childhood Apraxia of Speech
Primary: Speech Accuracy of Treated Items — -0.7; 10.6; -2.8; -1.4 percentage of accuracy (change score) — p=0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=70 Transcranial Doppler (TCD) Assessment During Early Anti-thrombotic Therapy After Bioprosthetic Aortic Valve Replacement
Aortic Valve Disease
Primary: Differences in the Rate of Doppler-detected Cerebral Micro Emboli Between the Two Prophylactic Treatments of Thrombosis — 1.1; 0.7; 1.0; 0.7 MES counts
N/A N=160 Progress of Mild Alzheimer's Disease in Participants on Acupuncture Versus Sham Acupuncture
Alzheimer Disease 1
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 12 Item Subscore (ADAS-Cog12) — -1.20; 0.36 point
Phase 2 N=225 A Study to Test Different Doses of BI 1569912 in People With Depression
Depressive Disorder, Major
Primary: Change From Baseline in MADRS Total Score at Week 6 — -10.3; -13.6; -10.6; -10.0 Units on a scale — p=0.5414
Phase 2 N=24 Comparison of Rimegepant and Placebo for Pain in IBS
Irritable Bowel Syndrome
Primary: Change in Abdominal Pain Scores — -12; -22.6 score on a scale — p=0.41
Phase 4 N=658 Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
Migraine
Primary: Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) — -2.1; -0.5 Migraine Days per month — p=<0.0001
Phase 3 N=530 Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Complicated Urinary Tract Infection · Acute Pyelonephritis
Primary: Percentage of Subjects With Overall Success at Test-of-Cure — 250; 93; 31; 43 Participants
Phase 1 N=50 A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
Healthy · Obese · Overweight
Primary: Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC[0-∞]) of Simvastatin and Its Metabolite Simvastatin Acid Following…
Phase 1 N=22 Biotin-RBC Transfusion in SCD
Sickle Cell Disease
Primary: Percentage of Biotin Labeled RBCs — 97.3; 80; 21 percentage of biotin-labeled RBCs
N/A N=47 Chronic-disease Self-management Program in Patients Living With Long-COVID in Puerto Rico
Long Covid19
Primary: Assessment of the Impact of Health-related Quality of Life — 4; 3; 4; 6 Participants
Phase 1 N=8 A Study in Healthy Men to Test How BI 1569912 is Processed in the Body
Healthy
Primary: Fraction Excreted in Urine as Percentage of the Administered Dose Over the Time Interval From 0 to the Last Quantifiable Time Point (fe Urine,0-tz) of…
Phase 2 N=186 Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 32.1; 79.5; 94.4 Percentage of participants
Phase 1 N=47 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
Colorectal Adenocarcinoma · Metastatic Pancreatic Adenocarcinoma · Recurrent Colorectal Carcinoma
Primary: Recommended Phase II Dose of the Combination of XL888 and Pembrolizumab as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version…
N/A N=320 Room to Grow Evaluation for Children
Parenting · Child Development
Primary: Mean Score of Depressive Symptoms Using the CES-D Scale — 5.59; 5.95; 4.17; 4.74 score on a scale
Phase 2 N=13 An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder
Alcohol Use Disorder
Primary: Percentage of Participants With Treatment Emergent Adverse Events — 11 Participants